The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.

ABSTRACT:

Objectives

Exploring the efficacy and safety of perioperative chemotherapy on patients with AGC at different clinical and pathological stages.

Methods

A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin (XELOX, arm C) was initiated in T3/4, node + gastric cancer patients (unclear). Each patient received an 8-cycle chemotherapy (3 weeks for one cycle). Group arms B and C received two cycles preoperatively, and six cycles postoperatively. Primary endpoints were R0 resection rate and DFS, and secondary endpoints included OS, ORR, DCR, and safety. This study was registered on Clinicaltrials.gov. NCT01516944.

Results

A total of 749 patients were randomly as

SUBMITTER: Zhao Q 

PROVIDER: S-EPMC7433829 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature